Clinical Effect of Nimodipine Combined with Rosuvastatin Calcium in the Treatment of Hypertensive Intracerebral Hemorrhage

Objective: To explore the clinical effect of nimodipine combined with rosuvastatin calcium in the treatment of hypertensive intracerebral hemorrhage. Methods: Sixty patients with hypertensive intracerebral hemorrhage from January 2023 to December 2023 were randomly divided into a control group (n = 30) and an observation group (n = 30). The control group received conventional treatment, while the observation group was treated with nimodipine + rosuvastatin calcium tablets. The neurological function, edema volume, hematoma volume, adverse reactions, and treatment efficiency were compared between the two groups. Results: After treatment, compared with the control group, the edema volume, hematoma volume index, and NIHSS score in the observation group were all reduced, and the differences were extremely significant (P < 0.001). The clinical efficacy of the observation group was 93.33%, which was much higher than the 66.67% of the control group, and the difference was significant (P < 0.05). The incidence of adverse reactions in the observation group was 3.33%, which was far lower than the 30.00% of the control group, and the difference was significant (P < 0.05). Conclusion: Nimodipine combined with rosuvastatin calcium in the treatment of hypertensive intracerebral hemorrhage shows significant advantages in improving edema volume and hematoma volume, promoting neurological recovery, improving clinical efficacy, and reducing the incidence of adverse reactions, thus having broad clinical application prospects.